JP2023500359A - 細胞外小胞、及び抗体の送達のためのその使用 - Google Patents

細胞外小胞、及び抗体の送達のためのその使用 Download PDF

Info

Publication number
JP2023500359A
JP2023500359A JP2022526371A JP2022526371A JP2023500359A JP 2023500359 A JP2023500359 A JP 2023500359A JP 2022526371 A JP2022526371 A JP 2022526371A JP 2022526371 A JP2022526371 A JP 2022526371A JP 2023500359 A JP2023500359 A JP 2023500359A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding portion
evs
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500359A5 (https=
Inventor
スティーブン， エル． スタイス，
レイモンド スウェテンバーグ，
リアナ ケイ． カーティ，
Original Assignee
アルナ バイオ， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルナ バイオ， インコーポレーテッド filed Critical アルナ バイオ， インコーポレーテッド
Publication of JP2023500359A publication Critical patent/JP2023500359A/ja
Publication of JP2023500359A5 publication Critical patent/JP2023500359A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Botany (AREA)
  • Gynecology & Obstetrics (AREA)
JP2022526371A 2019-11-04 2020-11-04 細胞外小胞、及び抗体の送達のためのその使用 Pending JP2023500359A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930178P 2019-11-04 2019-11-04
US62/930,178 2019-11-04
PCT/US2020/058968 WO2021092080A1 (en) 2019-11-04 2020-11-04 Extracellular vesicles and uses thereof for antibody delivery

Publications (2)

Publication Number Publication Date
JP2023500359A true JP2023500359A (ja) 2023-01-05
JP2023500359A5 JP2023500359A5 (https=) 2023-11-10

Family

ID=75848183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526371A Pending JP2023500359A (ja) 2019-11-04 2020-11-04 細胞外小胞、及び抗体の送達のためのその使用

Country Status (6)

Country Link
US (1) US20220409738A1 (https=)
EP (1) EP4054631A4 (https=)
JP (1) JP2023500359A (https=)
KR (1) KR20230004424A (https=)
CN (1) CN115942957A (https=)
WO (1) WO2021092080A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023178500A1 (en) * 2022-03-22 2023-09-28 Beijing Theraxyte Bioscience Co. Ltd. Therapeutic vesicles and methods of processing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149432B2 (en) * 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
EP3057662A4 (en) * 2013-10-17 2017-03-29 Children's Hospital Los Angeles Antibody dependent exosome therapy
JP7075594B2 (ja) * 2015-11-18 2022-05-26 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド 神経細胞の細胞外小胞
US11458097B2 (en) * 2016-03-30 2022-10-04 The University Of North Carolina At Chapel Hill Biological agent-exosome compositions and uses thereof
CA3093849A1 (en) * 2018-03-23 2019-09-26 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist
US11519033B2 (en) * 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
WO2020198626A1 (en) * 2019-03-27 2020-10-01 University Of Georgia Research Foundation, Inc. Methods of making targeted vesicles, and compositions made thereby

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMINI, A. ET AL.: "PF07.03 To study anti-tau antibody loading and neuronal uptake efficiency of human bone marrow mesen", ‘ISEV2018 ABSTRACT BOOK’, JOURNAL OF EXTRACELLULAR VESICLES, vol. Vol.7, Suppl.1, JPN6024048322, 2018, pages 156 - 157, ISSN: 0005700230 *
HANEY, M. J. ET AL.: "TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the", ADVANCED HEALTHCARE MATERIALS, vol. 8, no. 11, JPN6024048319, 18 April 2019 (2019-04-18), pages 1801271, ISSN: 0005700233 *
VOGEL, A. D. ET AL.: "Neural stem cell derived extracellular vesicles: Attributes and prospects for treating neurodegenera", EBIOMEDICINE, vol. 38, JPN6024048321, 2018, pages 273 - 282, ISSN: 0005700231 *
WANG, M. ET AL.: "Integrating Protein Engineering and Bioorthogonal Click Conjugation for Extracellular Vesicle Modula", PLOS ONE, vol. 10, no. 11, JPN6024048320, 2015, pages 0141860, XP055637569, ISSN: 0005700232, DOI: 10.1371/journal.pone.0141860 *

Also Published As

Publication number Publication date
CN115942957A (zh) 2023-04-07
KR20230004424A (ko) 2023-01-06
EP4054631A4 (en) 2024-07-10
US20220409738A1 (en) 2022-12-29
WO2021092080A1 (en) 2021-05-14
EP4054631A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
JP6965311B2 (ja) 二重特異的融合タンパク質
JP7197464B2 (ja) 結合タンパク質－小分子コンジュゲートのｅｖ媒介送達
CN111356701B (zh) 抗α-突触核蛋白抗体及其用途
JP2021500367A (ja) 操作された細胞外小胞の親和性精製
CN102803472B (zh) 去除了外来表型的由多能干细胞分化的子代细胞
JP2017014286A (ja) 選択的ｎｇｆ経路インヒビターとしてのヒト抗ｎｇｆ中和抗体
JP2021504412A (ja) Ｃｄ５＋細胞の枯渇のための組成物および方法
US20240026031A1 (en) Degradation of surface proteins using bispecific binding agent
JP2023515708A (ja) 中枢神経系送達のための結合剤及びその使用
WO2022147587A9 (en) Extracellular vesicle-mediated delivery to cells
CN111886251A (zh) 抗a-syn/igf1r的双特异性抗体及其用途
CA3118692A1 (en) Cell-based gene therapy for neurodegenerative diseases
WO2010122961A1 (ja) 細胞医薬の製造方法
US20220409738A1 (en) Extracellular vesicles and uses thereof for antibody delivery
Primorac et al. Clinical Applications of Extracellular Vesicles: Promises and Pitfalls
JP2024500115A (ja) 抗体デリバリー
US12091448B2 (en) Binding molecule able to neutralize PROX1 protein
WO2023069971A2 (en) Cd24-loaded vesicles for treatment of cytokine storm and other conditions
WO2023220639A2 (en) Methods and compositions for improved memory in the aging
US20200306296A1 (en) Induced tissue regeneration using extracellular vesicles
US20200277390A1 (en) Ligands binding to prion protein for use in the treatment of synucleinopathies
JP2022512923A (ja) 繊維芽細胞を用いた悪液質の治療及びその生成物
US20240092893A1 (en) Ldl receptor-directed bispecific binding agent-ligand fusions for the degradation of target proteins
Mobasheri Clinical Applications of Extracellular Vesicles: Promises and Pitfalls
박수민 Immunomodulation by extracellular vesicles from deferoxamine preconditioned canine adipose tissue derived mesenchymal stem cells in experimental autoimmune encephalomyelitis mouse model

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251002